Lac-Phe mediates the effects of metformin on food intake and body weight
March 18, 2024 / Obesity / Body Weight / Anti-diabetic
Metformin is a widely prescribed anti-diabetic medicine that also reduces body weight. There is ongoing debate about the mechanisms that mediate metformin’s effects on energy balance. Here, we show that metformin is a powerful pharmacological inducer of the anorexigenic metabolite N-lactoyl-phenylalanine (Lac-Phe) in cells, in mice and two independent human cohorts.
Metabolic syndrome increases the risk of all types of cancer, study finds
March 13, 2024 / Metabolic Syndrome / Cancer / Obesity
It’s been established that metabolic syndrome and its underlying conditions are associated with cardiovascular issues as well as type 2 diabetesTrusted Source, but this new study shows how metabolic syndrome contributes to cancer risk over time.
Middle-age obesity is caused by changes in brain structure
March 18, 2024 / Obesity / Heart Disease / Diabetes / Chronic Conditions
Middle-age obesity is a growing concern worldwide, linked to a myriad of health issues such as diabetes, heart disease, and other chronic conditions. Traditional understanding attributes this weight gain to a decrease in metabolism due to aging.
Kallistatin expression increases after weight loss, study reveals
March 18, 2024 / Weight Loss / Kallistatin / Obesity / Metabolism
After weight loss, people with overweight and obesity express more of the protein Kallistatin in subcutaneous white adipose tissue. This was demonstrated by researchers from the DZD in a recent study. In addition, Kallistatin improves metabolism and could open up new therapeutic options for people with obesity and type 2 diabetes in future. The results have now been published in Molecular Metabolism.
Research Using NMR Uncovers New Biomarkers of Metabolic Syndrome
March 18, 2024 / Metabolic Syndrome / Biomarkers / Diabetes
Metabolic syndrome (MetS) is a clustering of five conditions that includes abdominal obesity, diabetes, and high blood pressure. One quarter of the developed world population is estimated to have the condition (1). It is associated with the risk of coronary heart disease, stroke, and other conditions that affect the blood vessels (2). Diagnosis of MetS can be challenging as there is a lack of consensus about a definition of the condition. It is often associated with lifestyle factors such as poor diet and physical inactivity, but there are also genetic factors that put some people at higher risk.
Mouse models shed light on the effects of metformin use during pregnancy on offspring
March 18, 2024 / Women’s Health / Pregnancy / Diabetes / Metabolic Disorders
With the rise in gestational diabetes and metabolic disorders during pregnancy, metformin is also being prescribed more frequently. Although it is known that the oral antidiabetic agent can cross the placental barrier, the impacts on the brain development of the child are largely unknown. An interdisciplinary research team from the German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE) have now been able to demonstrate in a mouse model that although metformin has positive effects in pregnant animals, it does not in the offspring. The results were published in the specialist journal Molecular Metabolism.
Study shows bariatric surgery linked to cardiometabolic health improvements
March 18, 2024 / Cardiometabolic / Bariatric Surgery
Bariatric surgery can lead to significant cardiometabolic health improvements using a variety of measures, including blood pressure, cholesterol, glucose and hemoglobin A1C, according to a new study published in the Journal of the Endocrine Society.
How diabetes drug metformin can suppress hunger and help with weight loss
March 18, 2024 / Diabetes / Weight Loss / Obesity
The diabetes medication metformin increases the body’s production of a molecule that suppresses appetite, according to a studyTrusted Source by Stanford University in California published today in the journal Nature Metabolism.
This same molecule is also produced during and after vigorous exercise — a fact that was discoveredTrusted Source two years ago by researchers at Stanford and Baylor University in Texas.
FDA Approves First Gene Therapy for Rare Pediatric Disease
March 18, 2024 / Gene Therapy / Pediatric Disease / FDA
The FDA approved 55 new drugs and 34 cell and gene therapies in 2023. But it’s not always good news that companies have to deliver to their stakeholders; the year also had its fair share of Complete Response Letters.
Boehringer Ingelheim and Roche Diagnostics collaborate to raise awareness of cardio-renal-metabolic diseases in the UAE
March 18, 2024 / Boehringer Ingelheim / Roche / Cardio-Renal-Metabolic Disease
Boehringer Ingelheim, one of the world’s leading research-driven biopharmaceutical companies, and Roche Diagnostics, a world leader in biotechnology, recently signed an agreement to raise awareness on cardiovascular, renal and metabolic (CRM) conditions in the UAE to help reduce the burden of interconnected CRM diseases and improve patient outcomes. The memorandum of understanding (MoU) that was signed in Dubai sets a focus on highlighting the importance of early diagnosis and calling for a holistic and multidisciplinary approach to CRM disease management.
8-hour time-restricted eating schedule may increase heart disease mortality
March 18, 2024 / Heart Disease / Cardiometabolic / Obesity
An analysis of over 20,000 U.S. adults found that people who limited their eating across less than 8 hours per day, a time-restricted eating plan, were more likely to die from cardiovascular disease compared to people who ate across 12-16 hours per day, according to preliminary research presented at the American Heart Association’s Epidemiology and Prevention│Lifestyle and Cardiometabolic Scientific Sessions 2024, March 18- 21, in Chicago. The meeting offers the latest science on population-based health and wellness and implications for lifestyle.
Metabolic health tracking using Ultrahuman M1 continuous glucose monitoring platform in non- and pre-diabetic Indians: a multi-armed observational study
March 18, 2024 / Metabolic Health / Diabetes
Continuous glucose monitoring (CGM) device adoption in non- and pre-diabetics for preventive healthcare has uncovered a paucity of benchmarking data on glycemic control and insulin resistance for the high-risk Indian/South Asian demographic. Furthermore, the correlational efficacy between digital applications-derived health scores and glycemic indices lacks clear supportive evidence.
Kallistatin found to contribute to the beneficial metabolic effects of weight loss
March 18, 2024 / Kallistatin / Obesity / Weight Loss / Type 2 Diabetes
After weight loss, people who are overweight and obese express more of the protein Kallistatin* in subcutaneous white adipose tissue. This was demonstrated by researchers from the DZD in a recent study. In addition, Kallistatin improves metabolism and could open up new therapeutic options for people with obesity and type 2 diabetes in the future. The results have now been published in Molecular Metabolism.
FDA Approves Madrigal’s Rezdiffra as First MASH Therapy
March 15, 2024 / FDA / MASH
In one of the year’s most highly anticipated decisions, the FDA approved Madrigal Pharmaceuticals’ resmetirom Thursday as the first-ever therapy for metabolic dysfunction-associated steatohepatitis.
Experts help bring first-of-its-kind drug for metabolic liver disease to the clinic
March 15, 2024 / Liver Disease
Liver disease specialists at the University of Chicago Medicine will soon begin prescribing a first-of-its-kind drug for treating advanced metabolic dysfunction-associated steatotic liver disease (MASLD)—formerly known as nonalcoholic fatty liver disease (NAFLD).
Industry Voices—The dawn of a new era in liver care: MASH therapeutics’ arrival
March 15, 2024 / FDA / Liver Disease / Liver Disease / Preventive Medicine
This represents a pivotal moment in healthcare and calls for a celebration.
This new therapeutic for advanced-stage liver disease is significant because, until now, diet and exercise were the only available treatment options.
It’s true this drug will be game-changing for physicians. More importantly, it will be life-changing for patients.
Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes
March 14, 2024 / Atrogi / Clinical Data / Type 2 Diabetes
Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces the full set of results from its Phase 1 a/b trial with ATR-258, its first-in-class treatment for type 2 diabetes (T2D). This clinical trial, conducted on both healthy volunteers and individuals with T2D, underscores the safety of ATR-258 as a novel β2-adrenoceptor agonist, offering a revolutionary approach to type 2 diabetes treatment.
Cardiometabolic Risks in Patients With Sleep-Disordered Breathing Identified With Metabolomic Profiling
March 14, 2024 / Cardiometabolic / Sleep Disorders
Metabolite profiling of patients with sleep-disordered breathing (SDB) can aid in the identification of individual cardiometabolic risks, according to a recent study published in Nature Communications.
Apple cider vinegar shows promise in weight loss and metabolic health
March 13, 2024 / Obesity / Metabolic Health
In the present randomized, double-blinded, placebo-controlled trial, researchers examined the safety and effectiveness of apple cider vinegar in lowering weight and improving lipid and glycemic profiles among young Lebanon residents with elevated body mass index (BMI) values.
Obese woman undergoes robotic surgery for diabetes at Jinnah Hospital
March 13, 2024 / Obesity / Diabetes
Professor Shahid Rasool, who led the operation, told Geo News that after this procedure, diabetic patients would not require any medicine or insulin to control blood sugar levels.
Weight loss drug Wegovy gains FDA approval to reduce heart disease risk
March 13, 2024 / Weight loss / FDA / Heart Disease
On March 8, the FDA approvedTrusted Source the semaglutide medication Wegovy to help reduce the risk of cardiovascular death, heart attack, and stroke in adults with heart disease who have obesity or overweight.
The indication recommends using semaglutide in addition to a reduced-calorie diet and increased physical activity.
Study links rising metabolic syndrome scores to increased cancer risk
March 12, 2024 / Metabolic Syndrome / Cancer
MetS is associated with multiple conditions that co-occur and increase the risk of type 2 diabetes, stroke, and heart disease. Some of the conditions associated with MetS include excess body fat around the waist, high blood pressure, abnormal cholesterol and triglyceride (TG), and high blood sugar levels.
Mediterranean diet linked to richer gut diversity, study finds
March 12, 2024 / Metabolic Health
n a recent study published in the journal Nutrients, researchers explored how following the Mediterranean diet (MD) influences the gut microbiome of healthy individuals through a well-defined cohort study.
Their results indicate that adhering to MD increases the species diversity of microbiota, offering insights into how it can lead to measurable health benefits.
Saghmos Therapeutics Announces Receipt of Notice of Allowance from Japanese Patent Office for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516
March 12, 2024 / Metabolic Disease / Cardio-Renal-Metabolic
Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced that it has received a Notice of Allowance from the Japanese Patent Office for a patent for its Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic modulator. The patent will provide exclusivity through 2037, with broad claims for the reduction of acute kidney injury in patients with chronic kidney disease (CKD) undergoing procedures with contrast dyes.
Risk of Cancer Higher for People Living with Worsening Metabolic Syndrome
March 12, 2024 / Metabolic Syndrome / Cancer Risk
A studyTrusted Source published online ahead of the April 1, 2024 print version of Cancer has found that worsening metabolic syndrome appears to increase the risk of developing cancer.
According to the National Heart, Lung, and Blood Institute, metabolic syndromeTrusted Source is a clustering of symptoms that increases a person’s risk for coronary heart disease, diabetes, and stroke.